PDCD1 and cancer: Therefore, this system shows great potential for testing immune-oncology therapies, including programmed cell death-1 (PD-1)/PD-ligand 1 (PD-L1) blockade and T-cell therapies for cancer patients within a time frame that is suitable for guiding cancer treatment in the clinic.